Generics: SPC Waiver will save money but increase litigation
Fresenius Kabi, Insud Pharma and other generic drug firms explain how the EU’s SPC manufacturing waiver in its compromised form will benefit them – but also how its notification clause could make litigation easier and more attractive to innovator drug companies. (Read more … )
In-house counsel share M&A due diligence tips
Uber, Nestlé and a luggage company speak to Patent Strategy about their due diligence difficulties during mergers and acquisitions and how they avoid the inherent portfolio analysis pitfalls. (Read more … )
Sign up to receive more content like this in Patent Strategy’s weekly newsletter.
